Biotricity, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Waqaas Al-Siddiq
- Full Time Employees
- 55
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 275 Shoreline Drive Redwood City CA United States of America 94065
- IPO Date
- Feb 16, 2018
- CIK
- 0001630113
- Website
- biotricity.com
- Similar Companies
- Business
- Biotricity, Inc. is a healthcare technology company specializing in remote cardiac diagnostics and chronic care management solutions. The company offers a comprehensive suite of products including the Bioflux System, which is a real-time mobile cardiac telemetry (MCT) device for diagnostic monitoring and ECG data transmission; the Biocare Cardiac Platform, a remote patient monitoring (RPM) solution that integrates data aggregation and alert systems for chronic cardiac conditions; and Biokit, a personal remote patient monitoring kit that includes tools for measuring temperature, blood pressure, and blood oxygen levels. Additionally, Biotricity markets the Bioheart device, a prescription-free, continuous heart rhythm monitor with three-channel capabilities. Founded in 2011 and headquartered in Redwood City, California, Biotricity operates primarily in the United States with ongoing efforts toward international regulatory clearances. The company serves healthcare providers, clinics, hospitals, and individual consumers by delivering advanced cardiac and vital sign monitoring technologies that enable early diagnosis, personalized treatment, and proactive health management. Recent major developments include strategic partnerships with multiple Group Purchasing Organizations (GPOs) covering approximately 90% of U.S. hospitals, significantly expanding Biotricity's market access and distribution channels. The company has also advanced its technology portfolio with increased automation driven by artificial intelligence (AI) and cloud-based analytics to improve operational efficiency and scalability. Financially, Biotricity reported notable revenue growth and margin improvement in fiscal 2025, achieving its first positive adjusted EBITDA and reducing operating expenses substantially, positioning it on a path toward scalable profitability entering fiscal 2026. These operational efficiencies are supported by increased recurring technology fees and enhanced adoption of the Biocare platform alongside a growing clinical footprint. In summary, Biotricity integrates real-time cardiac telemetry, AI-enhanced disease management analytics, and remote patient monitoring devices to deliver innovative healthcare solutions, supported by expanded strategic alliances and financial turnaround efforts in recent years.
Biotricity, Inc to Present at the LD Micro Invitational XVI
Financial Survey: 10x Genomics (NASDAQ:TXG) and Biotricity (OTCMKTS:BTCY)
Biotricity, Inc. (BTCY) Q3 2026 Earnings Call Transcript
Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDA
Biotricity to Announce Continued Growth in Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th
Comparing Biotricity (OTCMKTS:BTCY) & 111 (NASDAQ:YI)
Head-To-Head Analysis: Zepp Health (NYSE:ZEPP) versus Biotricity (OTCMKTS:BTCY)
3 Healthcare IT Stocks Up More Than 20% in 2025 With More Room to Run
Biotricity, Inc. (BTCY) Q2 2026 Earnings Call Transcript
Biotricity Inc. (BTCY) Reports Q2 Loss, Lags Revenue Estimates
Biotricity Strengthens Path to Scalable Profitability with Sustained Margins & Operational Efficiency in Second Quarter Fiscal 2026
Biotricity to Host Fiscal 2026 Second Quarter Financial Results and Business Update Call on November 14th
Health-E Commerce® and Biotricity® Collaborate to Expand Remote Cardiac Monitoring with Bioheart® for Flexible Spending Account (FSA) and Health Savings Account (HSA) Users
Biotricity and B-Secur Target the Consumer Wearables Market with Expansion of Next-Gen Cardiac Monitoring Platform
Are Medical Stocks Lagging Biotricity (BTCY) This Year?
Biotricity (BTCY) Upgraded to Buy: Here's Why
Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins
Biotricity to Host Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14th
BTCY: CA: A Fun Idea With Yield But Risky
Biotricity, Inc. (BTCY) Q4 2025 Earnings Conference Call Transcript